ST. LOUIS, Jan. 8, 2026 /PRNewswire/ -- Mercy is participating in a study designed to evaluate the clinical impact of GRAIL's Galleri ® multi-cancer early detection ...
Test demonstrates 89% sensitivity for detection of preclinical stage I/II high grade serous ovarian cancer at 98% specificity in average risk postmenopausal women WALTHAM, Mass., Oct. 28, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results